Saltzman Family’s Dis-Chem stake jumps $20 million

The South African multimillionaire Saltzman family, founders of Dis-Chem Pharmacies, have seen the market value of their joint stake in the company rise by $20 million since the start of the year as shares firmed on the Johannesburg Stock Exchange (JSE).

Family stake in Dis-Chem rises

The family owns 35.12 percent of Dis-Chem, equal to 302 million shares. Over the past 14 days, that stake has risen by R327.7 million ($20 million) at current exchange rates. The increase has propelled the market value of the family’s stake to R9.15 billion ($588 million).

The recent gain reflects a steady climb in Dis-Chem’s share price rather than a sharp rally, underscoring continued investor confidence in one of Africa’s largest healthcare retailers at a time when consumers remain under pressure from high living costs.

From a single pharmacy to a national chain

Dis-Chem was founded over 40 years ago by Lynette and Ivan Saltzman in Gauteng, one of the nine provinces of South Africa. The company began as a single pharmacy and has expanded into a nationwide chain, operating hundreds of outlets across South Africa.

The group has diversified beyond traditional pharmacies. Its operations now include family clinics, wound-care centers and a range of self-medication and wellness products. This has helped Dis-Chem build a consistent customer base and establish itself in the healthcare sector.

Dis-Chem shares gain 3.7% YTD 

Dis-Chem shares have risen 3.71 percent year-to-date, climbing from about R35 ($2.13) to R36.30. The increase has pushed the company’s market capitalization to around R31.2 billion ($1.9 billion), maintaining its position among the larger listed retailers on the JSE.

For the Saltzman family, the share gains reflect long-term value since founding Dis-Chem. The rise highlights the company’s growth and its position as a major player in South Africa’s retail healthcare sector, where it serves as a consistent contributor to the broader market.

The single-digit rally comes as investors factor in the resilience of healthcare spending compared with discretionary retail. This hedge has helped Dis-Chem withstand economic slowdowns, providing steadier performance when other retailers experience weaker demand.

Market eyes Dis-Chem full-year results

Attention is now turning to Dis-Chem’s upcoming full-year results. The company reported a solid half-year performance, with revenue from continuing operations climbing 11.1 percent to R16.8 billion ($1.02 billion). That segment remains the biggest contributor to group sales.

Overall group revenue rose 8.7 percent to R21.3 billion ($1.23 billion) during the period, driven by steady demand for pharmaceuticals, health products, and related services. Investors will closely watch whether this growth momentum continues.